clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT00720512 |
P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
P17 | country | Italy | Q38 |
P582 | end time | 2013-02-01 | |
P921 | main subject | rectum adenocarcinoma | Q18554959 |
P4135 | maximum age | 75 | |
P2899 | minimum age | 18 | |
P1132 | number of participants | 184 | |
P4844 | research intervention | fluorouracil | Q238512 |
irinotecan | Q412197 | ||
calcium oxalate | Q412399 | ||
bevacizumab | Q413299 | ||
leucovorin calcium | Q27077063 | ||
P6153 | research site | Azienda Ospedaliera Universitaria Senese | Q17622143 |
P1813 | short name | BEBYP | |
P580 | start time | 2008-06-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB. |